At my local university I have heard rumors that there "is a high percentage of idle sequencer capacity worldwide." Unfortunately I was not able to directly ask the person making the claim where he got his information, so I'm trying to track down more information about that statement. Some basic Google searches haven't turned up anything interesting, so I'm hoping someone here can provide more perspective.
Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
-
Thanks for the mention, kopi-o!
This is a really interesting question. We’re working on tools that will allow us to estimate things like this in the future, but for now we can make a ‘back of the envelope’ calculation.
Let’s just look at HiSeqs (which would account for the majority of the world’s sequencing capacity). Illumina has stated that each HiSeq generates ~$300k in consumable revenue per year. If we assume each full HiSeq run costs $20k, then this translates to 15 runs per year. I would say the theoretical maximum runs would be 25/year (in the ‘high throughput’ mode). Therefore, HiSeqs are being run at ~60% of the maximum (15/25). 10 runs times 600Gb per run = 6Tb excess capacity per machine. Multiply that by the number of machines (let’s say 1000 to make the math easy) and you have 6 petabases of excess capacity per year.
If we do the same thing for MiSeqs…
$50k/year in consumables = 50 runs = ~33% of maximum capacity (3 per week).
1000 machines X 100 runs X 10Gb/run = 1Pb excess capacity per year.
I can’t find the stated revenue/year number for the PGM and Proton, but if you have that you could make similar calculations. Let’s just say they contribute another 1Pb of unused capacity/year, giving us a (very rough) total of 8Pb. Lots of factors could bump this number up (more instruments/higher throughputs) or down (theoretical max estimate not conservative enough), but it’s probably in the ballpark.
Cheers,
Shawn
Comment
-
There is no doubt that unused sequencing capacity exists but there are two facets to that question. For consumers: how to tap into it productively and simply? For providers: How to accurately estimate the spare capacity and make it available "just in time"?
At many universities items like sequencers are purchased from capital expenditure funds meant to boost infrastructure capacity for internal needs. As a result internal samples always have priority. We run a mix of several HiSeq/MiSeq and there are (rare) times when a machine or two idles for a length of time. We had thought about using that time but since we can't accurately predict the availability it was not very practical.
Most commercial customers are looking for sustained availability/capacity over a length of defined time, on the other hand dealing with small infrequent samples is not worth the logistics involved in handling/billing/delivery of data.
Comment
-
To add to what GenoMax mentioned, a lot of Universities bought and buy large capital equipment like sequencers without any strategic plan in place to actually make use of it. That's because traditionally, it has been simple for an individual PI to get a strategic funds grant to buy a piece of equipment without running it through anyone else at the institution to plan out operational logistics or costs.
So, I would hazard a guess (one I'm pretty confident on) that the vast majority of academic sequencers are not used to anywhere near their actual capacity, many likely never even come close to enough use to really justify their capital cost in the first place. In other words, funds would have been better spent assisting investigators to get their sequencing done elsewhere, rather then the expenditure of funds on an under-used local facility.
Obviously, I'm painting with a pretty broad brush, but I worked in academia for a long time, and I don't think I'm far off for many institutions (although there are definitely some exceptions out there). And the same thing can be said for a lot of other high cost capital equipment at Universities for a number of reasons (but we don't need to go there).Michael Black, Ph.D.
ScitoVation LLC. RTP, N.C.
Comment
-
Originally posted by scbaker View PostThanks for the mention, kopi-o!
This is a really interesting question. We’re working on tools that will allow us to estimate things like this in the future, but for now we can make a ‘back of the envelope’ calculation.
Let’s just look at HiSeqs (which would account for the majority of the world’s sequencing capacity). Illumina has stated that each HiSeq generates ~$300k in consumable revenue per year. If we assume each full HiSeq run costs $20k, then this translates to 15 runs per year. <snip>
Comment
-
Originally posted by mbblack View Post...So, I would hazard a guess (one I'm pretty confident on) that the vast majority of academic sequencers are not used to anywhere near their actual capacity, many likely never even come close to enough use to really justify their capital cost in the first place....
Comment
-
Originally posted by mbblack View PostTo add to what GenoMax mentioned, a lot of Universities bought and buy large capital equipment like sequencers without any strategic plan in place to actually make use of it. That's because traditionally, it has been simple for an individual PI to get a strategic funds grant to buy a piece of equipment without running it through anyone else at the institution to plan out operational logistics or costs.
So, I would hazard a guess (one I'm pretty confident on) that the vast majority of academic sequencers are not used to anywhere near their actual capacity, many likely never even come close to enough use to really justify their capital cost in the first place. In other words, funds would have been better spent assisting investigators to get their sequencing done elsewhere, rather then the expenditure of funds on an under-used local facility.
Obviously, I'm painting with a pretty broad brush, but I worked in academia for a long time, and I don't think I'm far off for many institutions (although there are definitely some exceptions out there). And the same thing can be said for a lot of other high cost capital equipment at Universities for a number of reasons (but we don't need to go there).
Comment
Latest Articles
Collapse
-
by seqadmin
The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...-
Channel: Articles
04-22-2024, 07:01 AM -
-
by seqadmin
Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...-
Channel: Articles
04-04-2024, 04:25 PM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, 04-25-2024, 11:49 AM
|
0 responses
19 views
0 likes
|
Last Post
by seqadmin
04-25-2024, 11:49 AM
|
||
Started by seqadmin, 04-24-2024, 08:47 AM
|
0 responses
19 views
0 likes
|
Last Post
by seqadmin
04-24-2024, 08:47 AM
|
||
Started by seqadmin, 04-11-2024, 12:08 PM
|
0 responses
62 views
0 likes
|
Last Post
by seqadmin
04-11-2024, 12:08 PM
|
||
Started by seqadmin, 04-10-2024, 10:19 PM
|
0 responses
60 views
0 likes
|
Last Post
by seqadmin
04-10-2024, 10:19 PM
|
Comment